The U.S. Food and Drug Administration (FDA) has recently intensified its focus on the cybersecurity of medical device manufacturing, emphasizing the need for robust security measures in operational technology (OT). This move comes in response to the increasing integration of connected devices and smart technologies in manufacturing processes, which, while enhancing efficiency, also introduce new vulnerabilities.
The warning is loud and clear
Manufacturers of medical devices are under rising pressure to secure operational technology (OT) systems. Recent warnings from the FDA have called for urgent improvements in how these manufacturers protect connected components used in device production. The risk isn’t theoretical. Weak OT security can directly compromise patient safety, public health, and national medical supply chains.
The FDA’s latest guidance outlines not only the risks, but also detailed expectationsand it’s sending a message: cybersecurity is no longer optional.
What exactly is OT and why does it matter?
Operational technology refers to the hardware and software systems that monitor or control industrial equipment. In medical manufacturing, this includes:
- Robotics on the assembly line
- Sensors measuring sterility
- Smart controls in drug delivery systems
- IIoT components managing device calibration
When these systems are connected to networks, they become cyber targets. A compromised sterilizer or dosing machine could affect product integrityor worse, endanger lives. OT security, once overlooked, is now front and center.
What’s new in the FDA’s expectations?
The agency’s latest white paper lays out a cybersecurity vision that includes:
- Secure-by-design implementation: Security must be integrated during system designnot as an afterthought.
- System zoning and segmentation: Manufacturers must isolate critical systems to limit attack surface.
- Real-time monitoring and visibility: Continuous oversight is essential to detect threats early.
- Risk-based prioritization: Not every vulnerability poses equal risk. Focus where it matters most.
- Vulnerability disclosure protocols: A coordinated response system must be in place to report and fix flaws fast.
This isn’t just adviceit’s a strategic framework. The shift in tone from “should” to “must” is evident.
Why now?
Several factors are accelerating this urgency:
- Ransomware attacks on hospitals and medtech vendors are increasing
- Healthcare is one of the most targeted sectors for cybercriminals
- Connected devices (IoMT) are now standard in manufacturing environments
- Regulatory expectations globally are rising in tandem
Healthcare supply chains have grown more complex and more digital. A single vulnerabilitydeep in a manufacturing systemcan ripple out and compromise thousands of devices.
Case study: Lessons from a real-world breach
A prominent medical imaging equipment manufacturer suffered a breach in 2024. Attackers infiltrated its OT environment through an unpatched remote access system used for maintenance. The threat actor remained undetected for weeks, exfiltrating data and interfering with calibration systems.
Production halted for 10 days.
That disruption caused delays in diagnostic devices reaching hospitals. A product recall followed. Reputational damage was extensive. Regulatory fines were issued.
Had secure-by-design principles been enforced, the breach could have been preventedor detected far earlier.
How this aligns with global trends
The FDA is not alone. Regulatory agencies around the world are issuing similar guidance. Consider:
- EU MDR and IVDR increasingly mention cybersecurity as part of product safety
- Singapore’s HCSA regulations call for proactive vulnerability monitoring
- Canada’s Health Products and Food Branch (HPFB) expects digital risk management as a lifecycle responsibility
- Global harmonization efforts are underway through IMDRF and ISO committees
Cybersecurity is becoming a shared international obligation in medtech compliance.
Where compliance and cybersecurity meet
A key theme in the FDA’s communication is integrationcybersecurity must be part of quality system regulations and risk management processes.
Applicable regulations include:
- 21 CFR Part 820 – design control and risk management
- Section 524B – new authority to require detailed cybersecurity plans in submissions
- Premarket guidance on cybersecurity – updated requirements for labeling, controls, and documentation
- Postmarket guidance – ongoing monitoring and coordinated vulnerability disclosure
This isn’t just IT’s problem. Quality teams, regulatory affairs, engineering, and compliance units must align to meet these standards.
Strategic steps manufacturers can take now
To get ahead of enforcementand reduce actual riskmedical product companies should prioritize:
- Security architecture reviews for existing OT environments
- Zero trust segmentation within factory networks
- OT asset inventory and lifecycle mapping
- Security patching workflows specific to industrial hardware
- Incident response exercises that include manufacturing systems
- Board-level cybersecurity briefings focused on operational risk
- Workforce training across rolesnot just IT teams
These actions demonstrate maturity. They also reduce operational downtime and potential liability.
Frequently asked questions
Who within the organization should own OT security?
Shared responsibility is ideal. Cybersecurity leads should partner with operations and engineering.
What happens if companies ignore the new guidance?
While not law, failure to align with the FDA’s recommendations could affect approvals and lead to enforcement actions.
Is OT risk really that different from IT risk?
Yes. OT often involves legacy equipment, longer lifecycles, and different protocols (e.g., Modbus, OPC). Security tools must be tailored.
Does this apply to all medical devices?
If OT is used in the manufacturing processyes. The FDA is especially concerned about risks affecting product integrity and supply chains.
Is the threat real or theoretical?
Very real. Multiple ransomware groups now target healthcare manufacturing, including sectors once considered niche.
Future outlook: What’s next for medical manufacturers?
The FDA’s OT cybersecurity initiative is just the beginning.
We can expect:
- Stricter enforcement tied to Section 524B
- More detailed premarket cybersecurity requirements
- International alignment around shared cyber standards
- Incentives for companies demonstrating advanced maturity
- Public pressure from consumers and hospitals seeking trusted suppliers
Early adopters will not only reduce riskthey’ll gain a competitive edge in reputation and readiness.
Final thoughts: Security is product quality
For too long, cybersecurity has been treated as a compliance checkbox. That mindset no longer suffices.
Medical device safety now includes digital safety. If a device is manufactured using compromised systems, its qualityand patient safetyare in question.
Regulators are signaling that security is a core component of product quality. Manufacturers who embrace this now will be best positioned for resilience and success.
